Navigation Links
National study explores the reaction and transport of tungsten in drinking water
Date:1/27/2011

the environment. More specifically it's an evaluation of how tungsten concentrations change along groundwater flow paths and modify the groundwater makeup.

When tungsten is exposed to oxygen -- a process called oxidation -- it often seeps into the ground and even into groundwater-bearing aquifers. During this process the tungsten can also mix with organic matter present in natural soils. In the presence of sulfur rich solutions, it forms thiotungstate complexes, which are also toxic.

To gather information the researchers are looking at pristine aquifers, like the Ogallala, as well as affected aquifers. Data from these findings can be used to create a conceptual model for this project and future studies, Datta said.

"Looking at emerging contaminants is one of the biggest things for an environmental geoscientist, and health is a big issue connected to any elemental or environmental study we do," Datta said.

"We are trying to approach this project from the standpoint of understanding this element and its behaviors in the environment before taking our findings to the general public so the situation can be addressed," he said.

Datta's previous work studied arsenic levels in the groundwater in West Bengal, India, and Bangladesh. Along with a K-State graduate student, he looked at why naturally occurring arsenic -- another toxin in nature -- got into groundwater from river-borne sediments, and finding well locations for cleaner water.


'/>"/>

Contact: Saugata Datta
sdatta@k-state.edu
785-532-2241
Kansas State University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Elsevier sponsors launch ceremonies for the International Year of Chemistry
2. International conference puts food safety under the microscope
3. US launches International Year of Chemistry Feb. 1 with panel of world-renowned chemists
4. Story tips from the Department of Energys Oak Ridge National Laboratory January 2011
5. Press registration opens for American Chemical Society National Meeting, March 27-31, 2011
6. National Cancer Institute renews Cancer Center designation for Huntsman Cancer Institute
7. Biophysical Society announces winners of 2011 International Travel Awards
8. Dodds contributes to new national study on nitrogen water pollution
9. SU biologist partners with National Park Service to study bison grazing in Yellowstone
10. Pacific Northwest National Laboratorys 2010 AGU tip sheet
11. National team of scientists peers into the future of stem cell biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
(Date:4/20/2015)... -- The announcement comes as demand for ... (GRM), Ireland,s foremost records management company, ... up an impressive track record of clients within the first ... records management sector in Dubai . As ... and employ a further eight staff members at its Irish ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... Today, the country,s leading health technology company, ... $15 million in new funding. This extension funding, led ... Ventures, brings Practice Fusion,s Series D funding to $85 ... million. The round was co-led by Longitude Capital, a ...
... (Dec. 9, 2013) For nearly half a century, ... ocular drug delivery that may someday replace eye drops, ... challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School ... Institute of Technology are one step closer to an ...
... gene that drives the development of tumours in over one ... time that the gene CUX1 has been broadly linked to ... deactivated, a biological pathway is activated that increases tumour growth. ... in the clinic and are in development thus highlighting a ...
Cached Biology News:Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 2Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 3Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month 2Gene promotes 1 in 100 of tumors 2
(Date:5/21/2015)... Imagine being able to probe and truly ... Being able to read faces and enjoy genuine invisible ... their thoughts and actions like never before. Use ... unique abstract paintings and video, or, play a completely ... as it creates action, dialog, and outcomes based on ...
(Date:5/21/2015)... May 21, 2015 As part of ... Center (BDWMC), Sun Health Foundation funded a $3.25 million ... inpatient pharmacy with the most up-to-date features and technology. ... 2. The pharmacy's 45 staff members will begin moving ... space in the coming days. , The current ...
(Date:5/21/2015)... of Prussia, PA (PRWEB) May 21, 2015 ... Julia O’Neill has joined the firm as senior statistician ... than 30 years of experience in the management and ... vaccines, biologics, pharmaceutical and chemical industries. , “We’re delighted ... our longstanding capabilities in data analytics,” said Dr. Philippe ...
(Date:5/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has ... Market Outlook 2020 " report to their offering. ... regenerative medicine is expected to have huge marketing potential. ... in the growth of deregulated organs. Several therapeutic molecules ... to form new tissue or sometimes organ transplant is ...
Breaking Biology Technology:5 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... , DALLAS, July 23 ... S PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) ... collecting data from a post approval study of MuGard in head and neck cancer ... a multi-center study expected to enroll a total of 280 patients, patients are provided ...
... , , ST. LOUIS, July ... Science and High Technology company, reported second quarter 2009 diluted EPS ... For the six months ended June 30, 2009, reported diluted ... the first six months of 2008. Excluding the negative impact ...
... , , SEATTLE, July 23 ... today announced the pricing of an underwritten public offering of 29,332,107 ... 7,333,027 shares of its common stock at a price to the ... purchase 0.25 shares of common stock, for gross proceeds of approximately ...
Cached Biology Technology:MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 3Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 2Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 3Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 4Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 5Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 6Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 7Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 8Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 9Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 10Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 11Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 12Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 13Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 14Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 15Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 16Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 17Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 2Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 3